Introduction {#S1}
============

Obstructive sleep apnea (OSA) affects 2--4% of the general adult population ([@B1]). OSA is characterized by repeated pharyngeal obstructions during sleep, resulting in airflow cessation (apnea) or reduction (hypopnea), frequent disruption of sleep, and hypoxic episodes. While obesity is the most significant risk factor, other risk factors, including smoking and use of sedative medications, have been found to play a significant role in OSA ([@B2]--[@B4]). OSA is associated with poor cardiometabolic outcome ([@B5]), increased risk of depression and anxiety, and impaired neurocognitive function ([@B6]).

People living with psychosis experience poor physical health and shortened life expectancy, with high prevalence of cardiometabolic risk factors, including obesity, hypertension, and diabetes ([@B7], [@B8]); impaired social and occupational function ([@B9]--[@B11]); and cognitive impairment ([@B11], [@B12]). Although OSA and psychotic disorders have many risk factors and poor clinical outcomes in common, few studies have focused on OSA in people with psychosis ([@B13], [@B14]). Several small studies have found a high prevalence of OSA in people with schizophrenia ([@B15]--[@B18]). High rates of obesity and smoking and frequent use of sedative medications observed in people with psychotic illnesses may contribute to the development of OSA. Alternatively, the pathological sequelae of OSA, including repeated episodes of hypoxia, sleep fragmentation, and oxidative stress, may precipitate or perpetuate psychopathological symptoms, metabolic disturbance, and impairment of neurocognitive and social functions in people with psychotic illness.

Aims {#S1-1}
----

Our primary aim was to examine the prevalence of OSA symptoms in a large representative sample of people with psychosis. Secondary aims included exploring the associations between OSA symptoms and variety of clinical outcomes, including physical health, risk factors for cardiovascular diseases, quality of life, social functioning, cognitive functioning, vocational engagement, and psychiatric symptoms. Finally, we examined the association between OSA symptoms in this population and known risk factors for OSA (e.g., obesity, alcohol and tobacco consumption, and sedative medication).

Our hypothesis was that clinical symptoms of OSA would be highly prevalent in people with psychosis and that clinical symptoms of OSA would correlate with increased cardiometabolic risk, poor cognitive and social functioning, and poor quality of life. Clinical symptoms of OSA would be associated with obesity, substance abuse, and the use of antipsychotic medications in a representative sample of people with psychotic disorders.

Materials and Methods {#S2}
=====================

Sample {#S2-1}
------

The 2010 Survey of High Impact Psychosis (SHIP) was the second Australian National survey of psychotic disorders. The survey catchment covered a population of 1.5 million people aged 18--64 years, approximately 10% of the Australian population in this age group. A two-phase design was used. In Phase 1, screening for psychosis took place in public mental health services and in non-governmental organizations supporting people with a mental illness. In Phase 2, people who screened positive for psychosis in Phase 1 were randomly selected and stratified by age group (18--34 years and 35--64 years) for interview and assessment. This process identified 7955 people who were screened positive for psychosis and eligible for interview. Potential participants were randomly selected and approached for participation in the study; 1825 participants who screened positive for psychosis were included and interviewed in Phase 2 of the study. The study was approved by the human research ethics committees at each of the seven study sites, and all participants provided written- informed consent. Full details of the survey methodology are described elsewhere ([@B10], [@B12]).

Demographics and Social Participation {#S2-2}
-------------------------------------

Gender, age, marital status, formal study educational level, and current employment were recorded. Item to assess the participant's involvement in meaningful activity was extracted from the main interview schedule to assess: 0 = employed in any job in last 12 months; 1 = home duties/caring for own children; 2 = caring for relatives; 3 = retired; 4 = volunteer/unpaid work; 5 = student; and 6 = no formal activity. Participants were divided into two groups: no formal activity and others. Diagnostic assessment was based on a semi-structured clinical research interview, the Diagnostic Interview for Psychosis (DIP) ([@B19]). Diagnoses were made according to the ICD-10 classification system ([@B20]).

Sleep Apnea Risk Assessment {#S2-3}
---------------------------

Questions assessing sleep apnea were taken from the University of Maryland Medical Centre Questionnaire for Sleep Apnea. These were self-rated assessments of the frequency and severity of snoring and pauses in breathing during sleep (a more severe symptom of OSA) over the previous 12 months. To assess the severity of the snoring, the following question was asked: "In the last 12 months, how frequently do you experience or have you been told about snoring loud enough to disturb the sleep of others?" \[0 = never; 1 = rarely (less than once a week); 2 = occasionally (1--3 times a week); 3 = frequently (\>3 times a week)\]. To assess the severity of pauses, the following question was asked: "In the last 12 months, how often have you been told that you have "pauses" in breathing or stop breathing during sleep?" \[0 = never; 1 = rarely (less than once a week); 2 = occasionally (1--3 times a week); 3 = frequently (\>3 times a week)\].

The assessment of the severity of disrupted sleep in the past week was made using Question 13 from the Assessment of Quality of Life (AQoL) Questionnaire-4D ([@B21]). The severity of disrupted sleep was rated as 1 = "I am able to sleep without difficulty most of the time"; 2 = "My sleep is interrupted some of the time, but I am usually able to go back to sleep without difficulty"; 3 = "My sleep is interrupted most nights, but I am usually able to go back to sleep without difficulty"; 4 = "I sleep in short bursts only. I am awake most of the night." Dichotomous categories for sleep measurement were created as follows: snoring (yes = reported snoring, no = no snoring); pauses (yes = reported pauses, no = no pauses); disrupted sleep (yes = at least some of the time, no = rarely).

Physical Activities and Physical Health {#S2-4}
---------------------------------------

Physical activity in the past 7 days was assessed using the International Physical Activity Questionnaire (IPAQ) short form ([@B22]). Electronic scales measuring up to 200 kg were used to assess weight (kilograms); height (metres) was taken against a measure on a wall. Body Mass Index (BMI) was calculated as weight/height^2^. Participants were categorized according to WHO criteria ([@B23]) as underweight (BMI \< 18.5), normal (BMI 18.5--24.99), overweight (BMI 25--29.99) or obese (BMI ≥ 30). Participants' absolute 5-year cardiovascular disease risk was determined by Framingham risk equation ([@B24]). Participants' history of diagnosed cardiovascular disease was ascertained by asking participants if they had ever been told by a doctor that they had any of the following: heart attack, angina, stroke/transient ischemic attack (TIA), or other heart disease, e.g., arrhythmias. They were asked to bring all medications to the interview, and those relevant to cardiometabolic conditions were identified. Details of all medication used in the 4 weeks prior to interview was recorded; this was based on self-report or review of medication charts ([@B25]).

Participants were also asked to provide a fasting blood sample for analysis of high density lipoprotein cholesterol, triglyceride, and plasma glucose levels. Metabolic syndrome was defined using the harmonized criteria developed by the International Diabetes Federation Task Force on Epidemiology and Prevention and related expert organizations ([@B26]). These criteria for metabolic syndrome require three of the following five risk factors to make the diagnosis: abdominal obesity (at-risk waist circumference ≥94 cm for men and ≥80 cm for women); at-risk diastolic and/or systolic blood pressure (systolic blood pressure ≥130 mmHg and/or a diastolic pressure ≥85 mmHg); at-risk levels of fasting blood glucose (≥5.6 mmol/L), triglycerides (≥1.7 mmol/L), or HDL-C (\<1.0 mmol/L for men and \<1.3 mmol/L for women). Abdominal obesity was defined as a waist circumference ≥94 cm for men and ≥80 cm for women. Hypertension was diagnosed if the person had a systolic blood pressure ≥130 mmHg and/or a diastolic pressure ≥85 mmHg. The thresholds for blood glucose, triglycerides, and lipids were: glucose ≥5.6 mmol/L; triglycerides ≥1.7 mmol/; HDL-C \<1.0 mmol/L for men and \<1.3 mmol/L for women. People receiving medications for hypertension, hyperlipidemia, or hyperglycemia were considered to meet the relevant criterion.

The IPAQ short form ([@B22]) was used to assess the amount of time participants spent in both vigorous and moderate exercise, and the amount of time they spent sitting on a typical weekday, during the last 7 days. The total time spent in various activities over the previous 7 days was classified according to Australian Bureau of Statistics criteria as applied in the National Survey of Mental Health and Wellbeing ([@B27]) into four levels of activity: very low, low, moderate, and high.

Psychotropic Medications {#S2-5}
------------------------

Information about antipsychotics, mood stabilizers, antidepressants, and other sedative medications taken in the 4 weeks prior to the interview was collected. Outpatients were asked to bring their medications to the interview, and for inpatients, the drug charts were reviewed. Antipsychotic medications were sub-classified as typical antipsychotics and atypical antipsychotics.

Substance Use {#S2-6}
-------------

Respondents were asked how often they had used alcohol, cannabis, amphetamines, and other drugs in the previous year, and were classified as: 1 = not used; 2 = monthly or less than monthly; 3 = weekly/daily ([@B19]). Alcohol dependence and risk categories were measured using the Alcohol Use Disorders Identification Test (AUDIT) ([@B28]). Lifetime diagnoses of alcohol, cannabis, and other substance abuse/dependence were assessed using the DIP ([@B19]). Caffeine consumption was quantified based on amount per day on average in the previous 4 weeks.

Diagnosis, Psychopathology, and Cognitive Function Assessment {#S2-7}
-------------------------------------------------------------

Diagnostic assessment was based on a semi-structured clinical research interview, the DIP ([@B19]). Diagnoses were made according to the ICD-10 classification system ([@B20]). Psychiatric symptoms were systematically interrogated using the DIP. Symptoms of hallucinations, delusions, or subjective thought disorder in the past 1 month and symptoms of anxiety, including worry, panic, anxiety, and obsession over the past 12 months were recorded. A brief cognitive assessment tool was employed. This comprised the: (i) National Adult Reading Test (NART) Revised ([@B29]) and (ii) Digit-Symbol Coding Test (DSCT) from the RBANS battery ([@B30]). Participants' subjective experience of forgetfulness over the past 12 months prior to the interview was assessed and the results were classified as: 1 = able to remember most things; 2 = somewhat forgetful; 3 = very forgetful.

Quality of Life Assessment {#S2-8}
--------------------------

The quality of life in the past week was assessed using The AQoL-4D 12-item instrument ([@B21]). The AQoL-4D independently models all the sub-dimensions of health (independent living, social relationships, physical senses, psychological well-being, and illness) and combines sub-models to obtain a multi-attribute utility score. Scores from the first four dimensions form the multi-attribute utility score. Algorithms for AQoL scoring were obtained from <http://www.aqol.com.au/index.php/scoring-algorithms?id=82>. Where negatively skewed (AQoL utility scores), data were transformed using the appropriate log transformations.

Statistical Analyses {#S2-9}
--------------------

Descriptive statistics were reported as means and SDs. Dichotomous categories were created: age (18--34 vs. 35--64); obesity -- BMI ≥ 30 (no vs. yes); absolute 5-year cardiovascular disease risk by Framingham risk equation (low vs. high = medium risk or high risk); any formal activity, including paid or unpaid work, or study (no vs. yes); subjective memory forgetfulness (no = able to remember most things vs. yes = somewhat forgetful or very forgetful); Fagerstrom nicotine dependence categories (low = low or very low vs. high = moderate, high, or very high); AUDIT risk (low vs. high = hazardous, harmful, or dependent). Univariate logistic regression was performed to explore associations between and among potential risk factors (independent variables) and the dependent variables (sleep apnea -- snore, sleep apnea -- pause, and disrupted sleep). Independent samples *t*-test was used to compare the mean scores for the AQoL. A binary logistic regression analysis was conducted to explore potential predictors of OSA symptoms. Variables were divided into four categories (cardiovascular risks; physical activity; social function; and substance abuse) and were entered into the model to estimate multivariate associations, with and without adjusting for age, gender, and BMI. Variables were included in the regression analyses, if they demonstrated significant association with OSA symptoms in the univariate analyses. All statistical analyses were performed with SPSS 22.0. The α value taken to indicate statistical significance was adjusted using Bonferroni correction for multiple comparisons of variables of the same category.

Results {#S3}
=======

Sociodemographic Data {#S3-1}
---------------------

The study sample comprised 1825 participants. Their mean age was 38.4 ± 11.2 years, and 59.6% were male. Most participants were single (61.2%); only 17% were married or in *de facto* relationships. More than half (53.2%) of the participants were not currently engaged in any meaningful activity such as paid or unpaid employment, volunteer job, career, home duty, or study. Most did not engage with any vigorous or moderate physical activity (76.9 and 69.2%, respectively); around half (48.5%) had engaged in any form of physical activity for less than 2 h per week. Nearly all participants (96.7%) had very low to low levels of exercise, according to ABS classification ([@B31]). The majority of participants were overweight, with 46.4% being obese (BMI ≥ 30), and the mean BMI was in the obese range (30.5 ± 7.5 SD) (Table [1](#T1){ref-type="table"}).

###### 

**Social demographics**.

                                                                                  *N*    \%     Mean ± SD
  ------------------------------------------------------------------------------- ------ ------ -------------
  **Gender**                                                                                    
  Men                                                                             1039   59.3   
  Women                                                                           714    40.7   
  **Age**                                                                                       38.4 ± 11.2
  18--34                                                                          773    42.4   
  35--64                                                                          1052   57.6   
  **Marital status**                                                                            
  Single, never married                                                           1117   61.2   
  Married/*de facto*                                                              312    17.0   
  Separated                                                                       376    20.6   
  Widowed                                                                         20     1.1    
  **Education level**                                                                           
  Complete year 9                                                                 410    22.5   
  Complete year 10                                                                535    29.3   
  Complete year 11                                                                283    15.5   
  Complete year 12                                                                574    31.5   
  **Physical activity**                                                                         
  Vigorous (none)                                                                 1448   79.6   
  Moderate (none)                                                                 1255   69.2   
  Walking (≤2 h/week)                                                             942    52.3   
  Total activity (≤2 h/week)                                                      881    48.5   
  Sitting (h/week)                                                                              45.7 ± 23.2
  **Level of exercise (ABS classification)**                                                    
  Very low                                                                        611    33.6   
  Low                                                                             1148   63.1   
  Moderate                                                                        54     3      
  High                                                                            6      0.3    
  **Meaningful activity (paid or unpaid work or study)**                                        
  Yes                                                                             854    46.8   
  No                                                                              971    53.2   
  **Difficulty reading, writing, or both**                                                      
  Yes                                                                             335    18.4   
  No                                                                              1490   81.6   
  **BMI -- criteria from World Health Organization**                                            30.5 ± 7.5
  Underweight                                                                     26     1.5    
  Normal                                                                          409    23.1   
  Overweight                                                                      516    29.1   
  Obese                                                                           823    46.4   
  **Any history of cardiovascular disease (including hypertension and stroke)**   505    28.5   
  **Diagnosis**                                                                                 
  Schizophrenia                                                                   857    47.0   
  Schizoaffective disorder                                                        293    16.1   
  Bipolar disorder with psychotic features                                        319    17.5   
  Depression with psychosis                                                       81     4.4    
  Delusional disorder                                                             92     5.0    
  Major depression without psychosis                                              158    8.7    
  Screen positive but did not meet full criteria for ICD-10 psychosis             25     1.4    

Prevalence of Symptoms of Sleep Disturbance {#S3-2}
-------------------------------------------

Nearly half of participants reported snoring during sleep (41.9%), while 17.4% reported that they stopped breathing during sleep and 7% reported frequent (\>3 times per week) episodes of stopping breathing during sleep. Over half of participants reported disrupted sleep at least some of the night (Table [2](#T2){ref-type="table"}).

###### 

**Sleep data of the study population (present state)**.

                            *N*    \%
  ------------------------- ------ ------
  **Sleep apnea snoring**          
  Never                     1018   58.1
  Rarely                    185    10.6
  Occasionally              213    12.2
  Frequently                337    19.2
  **Sleep apnea (pause)**          
  Never                     1418   82.6
  Rarely                    100    5.8
  Occasionally              78     4.5
  Frequently                121    7.0
  **Disrupted sleep**              
  Rarely                    837    46.3
  Some of the night         415    23.0
  Most of the night         318    17.6
  Short bursts sleep        236    13.1

The Association between Symptoms of Sleep Disturbance and Sociodemographic Characters {#S3-3}
-------------------------------------------------------------------------------------

Women reported snoring more frequently than men (*p* \< 0.001). Individuals aged 35--64 years had significantly higher odds of snoring (*p* \< 0.001), pauses (stopped breathing during sleep) (*p* \< 0.05), and disrupted sleep (*p* \< 0.05), compared with those aged 18--34 years. People reporting pauses in breathing during sleep were less likely to have any formal work or study activity (*p* \< 0.05), be in paid employment in the previous year (*p* \< 0.01), or be in paid employment in the previous week (*p* \< 0.001) (Table [3](#T3){ref-type="table"}).

###### 

**Univariate associations between participant characteristics and symptoms of sleep disturbance**.

                                                        Snore   Pause   Disruptive sleep                                                                                                                                                                              
  ----------------------------------------------------- ------- ------- ------------------------------------------ ------------------- ----- ------ ------------------------------------------ ------------------- ----- ------ ------------------------------------- -------------------
  **Gender**                                                                                                                                                                                                                                                          
  Men                                                   399     38.4    13[\*\*\*](#tfn3){ref-type="table-fn"}     1.43 (1.18, 1.73)   117   17.4   0.01                                       1.01 (0.78, 1.30)   557   51.8   3.6                                   1.20 (0.99, 1.45)
  Women                                                 336     47.1    122                                        17.5                412   56.4                                                                                                                     
  **Age**                                                                                                                                                                                                                                                             
  18--34                                                259     34.1    33.5[\*\*\*](#tfn3){ref-type="table-fn"}   1.77 (1.46, 2.16)   110   14.9   5.8[\*](#tfn1){ref-type="table-fn"}        1.37 (1.06, 1.77)   390   50.7   4.7[\*](#tfn1){ref-type="table-fn"}   1.23 (1.02, 1.48)
  35--64                                                476     47.9    189                                        19.3                579   55.8                                                                                                                     
  **Lives alone**                                                                                                                                                                                                                                                     
  Yes                                                   208     39.4    2.3                                        0.85 (0.69, 1.05)   82    15.9   1.2                                        0.86 (0.65, 1.13)   314   56     1.5                                   1.13 (0.93, 1.39)
  No                                                    514     43.3    210                                        18.1                637   52.8                                                                                                                     
  **Formal activity (paid or unpaid work, or study)**                                                                                                                                                                                                                 
  Yes                                                   345     41.5    0.14                                       0.97 (0.8, 1.17)    122   15     6.5[\*](#tfn1){ref-type="table-fn"}        0.72 (0.56, 0.93)   450   52.9   0.39                                  0.94 (0.78, 1.15)
  No                                                    390     42.3    177                                        19.6                519   54.3                                                                                                                     
  **Paid employment -- past year**                                                                                                                                                                                                                                    
  Yes                                                   232     39.9    1.4                                        0.88 (0.72, 108)    75    13.2   10.7[\*\*](#tfn2){ref-type="table-fn"}     0.62 (0.47, 0.83)   308   51.9   1.2                                   0.9 (0.74, 1.09)
  No                                                    503     42.9    224                                        19.5                661   54.5                                                                                                                     
  **Paid employment -- past week**                                                                                                                                                                                                                                    
  Yes                                                   156     40.9    0.2                                        0.95 (0.75, 1.2)    43    11.4   12.1[\*\*\*](#tfn3){ref-type="table-fn"}   0.55 (0.39, 0.77)   194   49.6   3.3                                   0.81 (0.65, 1.12)
  No                                                    579     42.2    256                                        19.1                775   54.8                                                                                                                     

*OR, odds ratio; CI, confidence interval*.

*\*p \< 0.05*.

*\*\*p \< 0.01*.

*\*\*\*p \< 0.001*.

Associations between Cardiovascular Risks and Symptoms of Sleep Disturbance {#S3-4}
---------------------------------------------------------------------------

People who reported snoring or pause had 1.5--3 times odds than those who did not to meet at-risk criteria for most key cardiometabolic risk factors, including elevated plasma triglycerides and fasting glucose, low HDL cholesterol, and hypertension. Participants reported snoring had odds ratio (OR) of 1.84 \[confidence interval (CI) 1.46, 2.32\], while those reported pause had OR of 2.26 (CI 1.66, 3.08) to meet criteria for metabolic syndrome and they had a higher 5-year risk of cardiovascular disease \[snore OR 1.56 (CI 1.23, 1.98); pause OD 1.65 (CI 1.23, 2.22), respectively\]. Snorers were more likely to have reported a history of cardiovascular disease, including angina, heart attack, other heart disease, e.g., arrhythmias, hypertension, and stoke/TIA \[OR 2.03 (CI 1.64, 2.52)\], as did those who reported pauses in breathing during sleep \[OR 2.19 (CI 1.69, 2.84)\]. Participants with disrupted sleep were more likely to meet the at-risk criteria for triglyceride levels, but not for other cardiovascular risk factors. Those with disrupted sleep were more likely to have a history of cardiovascular disease \[OR 1.47 (CI 1.19, 1.82)\] (Table [4](#T4){ref-type="table"}).

###### 

**Univariate associations between participant cardiovascular risks and symptoms of sleep disturbance**.

                                                                                  Snore   Pause   Disruptive sleep                                                                                                                                                                                   
  ------------------------------------------------------------------------------- ------- ------- ------------------------------------------ ------------------- ----- ------ ------------------------------------------ ------------------- ----- ------ ------------------------------------------ -------------------
  **Triglycerides level -criteria from IDF criteria**                                                                                                                                                                                                                                                
  At risk                                                                         287     48.2    12.4[\*\*\*](#tfn6){ref-type="table-fn"}   1.5 (1.2, 1.88)     141   24.2   33.4[\*\*\*](#tfn6){ref-type="table-fn"}   2.44 (1.79, 3.33)   350   57.3   6.5                                        1.33 (1.07, 1.66)
  Not at risk                                                                     247     38.2    73                                         11.6                333   50.2                                                                                                                          
  **Fasting plasma glucose level -- criteria from IDF criteria**                                                                                                                                                                                                                                     
  At risk                                                                         177     49.6    8.9[\*\*](#tfn5){ref-type="table-fn"}      1.45 (1.14, 1.86)   76    22     6                                          1.47 (1.08, 2.02)   205   56     1.2                                        1.15 (0.9, 1.47)
  Not at risk                                                                     357     40.3    139                                        16                  478   52.6                                                                                                                          
  **Blood pressure systolic and diastolic -- IDF criteria**                                                                                                                                                                                                                                          
  At risk                                                                         406     48.8    30.9[\*\*\*](#tfn6){ref-type="table-fn"}   1.73 (1.43, 2.1)    168   20.7   11[\*\*\*](#tfn6){ref-type="table-fn"}     1.54 (1.19, 1.98)   465   54.5   0.6                                        1.08 (0.89, 1.3)
  Not at risk                                                                     310     35.5    125                                        14.6                474   52.7                                                                                                                          
  **BMI: overweight -- IDF criteria**                                                                                                                                                                                                                                                                
  Yes                                                                             599     46.5    41.2[\*\*\*](#tfn6){ref-type="table-fn"}   2.16 (1.7, 2.7)     263   20.8   37.5[\*\*\*](#tfn6){ref-type="table-fn"}   3.17 (2.16, 4.66)   701   52.8   0.8                                        0.91 (0.73, 1.13)
  No                                                                              122     28.7    32                                         7.7                 240   55.3                                                                                                                          
  **HDL level -- IDF criteria**                                                                                                                                                                                                                                                                      
  At risk                                                                         286     46.4    5.8                                        1.32 (1.05, 1.66)   130   21.6   13.1[\*\*\*](#tfn6){ref-type="table-fn"}   1.74 (1.29, 2.36)   343   54.5   0.4                                        1.08 (0.86, 1.34)
  Not at risk                                                                     244     39.5    82                                         13.6                336   52.7                                                                                                                          
  **Metabolic syndrome -- IDF criteria**                                                                                                                                                                                                                                                             
  At risk                                                                         308     50.6    27.4[\*\*\*](#tfn6){ref-type="table-fn"}   1.84 (1.46, 2.32)   140   23.6   27.2[\*\*\*](#tfn6){ref-type="table-fn"}   2.26 (1.66, 3.08)   347   55.6   1.7                                        1.16 (0.93, 1.45)
  Not at risk                                                                     218     35.7    72                                         12                  327   52                                                                                                                            
  **Absolute cardiovascular disease 5-year risk -- Framingham risk equation**                                                                                                                                                                                                                        
  High                                                                            205     52      13.4[\*\*\*](#tfn6){ref-type="table-fn"}   1.56 (1.23, 1.98)   92    24     11[\*\*\*](#tfn6){ref-type="table-fn"}     1.65 (1.23, 2.22)   245   60.3   9.5[\*](#tfn4){ref-type="table-fn"}        1.45 (1.15, 1.84)
  Low                                                                             361     41      138                                        16                  461   51.2                                                                                                                          
  **Any history of cardiovascular disease (including hypertension and stroke)**                                                                                                                                                                                                                      
  Yes                                                                             263     54.6    43.2[\*\*\*](#tfn6){ref-type="table-fn"}   2.03 (1.64, 2.52)   124   26.3   35.5[\*\*\*](#tfn6){ref-type="table-fn"}   2.19 (1.69, 2.84)   300   60.4   12.9[\*\*\*](#tfn6){ref-type="table-fn"}   1.47 (1.19, 1.82)
  No                                                                              459     37.1    170                                        14.0                644   50.9                                                                                                                          

*OR, odds ratio; CI, confidence interval; IDF, International Diabetes Federation; BMI, body mass index; HDL, high density lipoprotein*.

*\*p \< 0.05*.

*\*\*p \< 0.01*.

*\*\*\*p \< 0.001*.

Associations between Level of Physical Activities, Quality of Life, Psychopathology, and Symptoms of Sleep Disturbance {#S3-5}
----------------------------------------------------------------------------------------------------------------------

Participants with pauses in breathing during sleep, but not snoring or interrupted, had higher odds of not to engage in any vigorous activity \[OR 1.6 (CI 1.14, 2.26)\] or total physical activity \[OR 1.53 (CI 1.09, 2.16)\]. Participants reporting pauses in breathing during sleep had lower scores on measures of total quality of life (*p* \< 0.001), independent living (*p* \< 0.05), and psychological wellbeing (*p* \< 0.001) when compared with those without pauses (Table [5](#T5){ref-type="table"}).

###### 

**Univariate associations between participant physical activities, quality of life, and symptoms of sleep disturbance**.

                                   Snore   Pause   Disruptive sleep                                                                                                                                                
  -------------------------------- ------- ------- ------------------ ------------------- ----- ------ --------------------------------------- ------------------- -------------- ------ ----- ------------------- --
  **Vigorous activity (h/week)**                                                                                                                                                                                   
  0                                598     43.2    3.8                1.27 (1.0, 1.6)     254   18.7   7.5[\*\*](#tfn8){ref-type="table-fn"}   1.6 (1.14, 2.26)    770            53.7   0.0   1.0 (0.8, 1.27)     
  \>0                              137     37.5    45                 12.6                198   53.5                                                                                                               
  **Moderate activity (h/week)**                                                                                                                                                                                   
  0                                493     41.2    1.0                0.9 (0.74, 1.11)    207   17.6   0.9                                     1.03 (0.79, 1.36)   664            53.3   0.2   0.96 (0.78, 1.17)   
  \>0                              239     43.7    91                 17.1                301   54.4                                                                                                               
  **Walk (h/week)**                                                                                                                                                                                                
  ≤2                               389     43.4    2.0                1.15 (0.95, 1.39)   169   19.3   4.2                                     1.3 (1.0, 1.68)     510            54.6   0.8   1.1 (0.9, 1.31)     
  \>2                              336     40.1    128                15.5                449   52.5                                                                                                               
  **Total activity (h/week)**                                                                                                                                                                                      
  0                                105     47.7    3.4                1.3 (0.98, 1.73)    50    23.4   6.0[\*](#tfn7){ref-type="table-fn"}     1.53 (1.09, 2.16)   122            54.2   0.0   1.03 (0.77, 1.36)   
  \>0                              630     41.2    249                16.6                846   53.6                                                                                                               
                                                                                                                                                                                                                   
                                                   **Mean**           **SD**                           **Mean**                                **SD**                                                              
                                                                                                                                                                                                                   
  AQoL (log)                       No      985     −0.39              0.38                NS    1377   −0.37                                   0.35                *P* \< 0.001                                    
                                   Yes     713     −0.40              0.36                NS    285    −0.47                                   0.41                                                                
  Indep living (log)               No      1008    −0.07              0.14                NS    1407   −0.07                                   0.14                *P* \< 0.05                                     
                                   Yes     728     −0.08              0.14                      293    −0.09                                   0.15                                                                
  Social rel (log)                 No      991     −0.26              0.32                NS    1389   −0.25                                   0.31                NS                                              
                                   Yes     718     −0.24              0.29                      287    −0.26                                   0.30                                                                
  Physic sense (log)               No      1012    −0.03              0.06                NS    1412   −0.03                                   0.05                NS                                              
                                   Yes     732     −0.03              0.05                      296    −0.03                                   0.06                                                                
  Psy well-being (log)             No      1009    −0.09              0.15                NS    1409   −0.09                                   0.14                *P* = 0.000                                     
                                   Yes     730     −0.10              0.14                      294    −0.13                                   0.18                                                                

*OR, odds ratio; CI, confidence interval; AQoL (log), algorithms for the Assessment of Quality of Life-4D multi-attribute utility score; Indep living (log), algorithms for independent living; Social rel (log), algorithms for social relationships; Physic sense (log), algorithms for physical senses; Psy well-being (log), algorithms for psychological well-being*.

*\*p \< 0.05*.

*\*\*p \< 0.01*.

*\*\*\*p \< 0.001*.

Participants with disrupted sleep but not snoring or pauses in breathing during sleep had higher odds of experiencing hallucinations, delusions or subjective thought disorder (*p* \< 0.001), depressive symptoms (*p* \< 0.001), and manic symptoms (*p* \< 0.001) in the past month. Anxiety symptoms were more likely to occur in those whose sleep was characterized by snoring (*p* \< 0.01), pauses (*p* \< 0.001), and disruption (*p* \< 0.001) (Table [6](#T6){ref-type="table"}).

###### 

**Univariate associations between subjects' psychopathology at present state and symptoms of sleep disturbance**.

                                                                                      Snore   Pause   Disruptive sleep                                                                                                                                                                                   
  ----------------------------------------------------------------------------------- ------- ------- ---------------------------------------- ------------------- ----- ------ ------------------------------------------- ------------------- ----- ------ ------------------------------------------- -------------------
  **Hallucinations, delusions, or subjective thought disorder in the past 1 month**                                                                                                                                                                                                                      
  Yes                                                                                 404     41.5    0.1                                      1.02 (0.85, 1.24)   182   19.1   4.4                                         1.28 (0.99, 1.64)   576   57.4   12.9[\*\*\*](#tfn12){ref-type="table-fn"}   1.41 (1.17, 1.7)
  No                                                                                  331     42.4    117                                      15.3                393   48.9                                                                                                                            
  **Any depressive symptoms in the past 1 month**                                                                                                                                                                                                                                                        
  Yes                                                                                 210     41.5    0.1                                      0.98 (0.79, 1.2)    97    19.8   2.7                                         1.25 (0.96, 1.64)   366   70.2   81.1[\*\*\*](#tfn12){ref-type="table-fn"}   2.67 (2.15, 3.32)
  No                                                                                  525     42.1    202                                      16.5                603   46.9                                                                                                                            
  **Screen for mania over the past 1 month**                                                                                                                                                                                                                                                             
  Yes                                                                                 75      48.4    2.9                                      1.33 (0.96, 1.85)   23    15.4   0.4                                         0.85 (0.54, 1.36)   114   72.2   23.8[\*\*\*](#tfn12){ref-type="table-fn"}   2.4 (1.68, 3.45)
  No                                                                                  660     41.3    276                                      17.6                855   51.9                                                                                                                            
  **Positive general rating of anxiety or phobia in the past 12 months**                                                                                                                                                                                                                                 
  Yes                                                                                 466     44.6    7.8[\*\*](#tfn11){ref-type="table-fn"}   1.32 (1.09, 1.6)    209   20.4   15.7[\*\*\*](#tfn12){ref-type="table-fn"}   1.71 (1.31, 2.24)   663   61.3   63.8[\*\*\*](#tfn12){ref-type="table-fn"}   2.17 (1.79, 2.63)
  No                                                                                  269     37.9    90                                       13.0                306   42.2                                                                                                                            

*OR, odds ratio; CI, confidence interval*.

*\*p \< 0.05*.

*\*\*p \< 0.01*.

*\*\*\*p \< 0.001*.

Associations between Psychotropic Medications and Symptoms of Sleep Disturbance {#S3-6}
-------------------------------------------------------------------------------

Participants taking atypical antipsychotic medications (including clozapine) had lower odds of reporting disrupted sleep than those not taking atypical antipsychotics (*p* \< 0.001, respectively). Atypical antipsychotics were not associated with snoring or pauses in breathing during sleep. Mood stabilizers were associated with increased odds of snoring (*p* \< 0.001) and pauses in breathing during sleep (*p* \< 0.05), but there was no association with disrupted sleep. Taking an antidepressant was associated with an increased likelihood of snoring (*p* \< 0.001) and a reduced likelihood of disrupted sleep (*p* \< 0.001), but had no significant association with pauses in breathing during sleep (Table [7](#T7){ref-type="table"}).

###### 

**Univariate associations between participants' psychotropic medications and symptoms of sleep disturbance**.

                                Snore   Pause   Disruptive sleep                                                                                                                                                                                 
  ----------------------------- ------- ------- ------------------------------------------- ------------------- ----- ------ -------------------------------------- ------------------- ----- ------ ------------------------------------------- -------------------
  **Typical antipsychotics**                                                                                                                                                                                                                     
  Yes                           156     44.4    1.1                                         1.14 (0.9, 1.44)    63    18.4   0.3                                    1.1 (0.8, 1.48)     186   51.7   0.7                                         0.91 (0.72, 1.14)
  No                            579     41.3    236                                         17.2                783   54.1                                                                                                                       
  **Atypical antipsychotics**                                                                                                                                                                                                                    
  Yes                           526     41.9    0.0                                         1.0 (0.81, 1.23)    203   16.5   2.3                                    0.81 (0.62, 1.06)   651   50.5   18.5[\*\*\*](#tfn15){ref-type="table-fn"}   0.63 (0.52, 0.78)
  No                            209     42.0    96                                          19.6                318   61.6                                                                                                                       
  **Mood stabilizer**                                                                                                                                                                                                                            
  Yes                           237     50.7    20.3[\*\*\*](#tfn15){ref-type="table-fn"}   1.63 (1.32, 2.02)   92    20     3.9[\*](#tfn13){ref-type="table-fn"}   1.32 (1.0, 1.73)    251   51.8   1.0                                         0.9 (0.73, 1.11)
  No                            498     38.7    207                                         16.3                718   54.4                                                                                                                       
  **Antidepressant**                                                                                                                                                                                                                             
  Yes                           307     47.7    11.1[\*\*\*](#tfn15){ref-type="table-fn"}   1.39 (1.15, 1.69)   126   19.7   3.7                                    1.28 (0.99, 1.65)   405   60.1   17.9[\*\*\*](#tfn15){ref-type="table-fn"}   1.52 (1.25, 1.84)
  No                            428     38.9    173                                         16.1                564   49.8                                                                                                                       
  **Clozapine**                                                                                                                                                                                                                                  
  Yes                           118     41.7    0.0                                         1.0 (0.76, 1.28)    49    17.6   0.0                                    1.0 (0.72, 1.42)    126   42.6   17.5[\*\*\*](#tfn15){ref-type="table-fn"}   0.59 (0.46, 0.75)
  No                            617     42.0    250                                         17.4                843   55.8                                                                                                                       

*OR, odds ratio; CI, confidence interval*.

*\*p \< 0.05*.

*\*\*p \< 0.01*.

*\*\*\*p \< 0.001*.

Associations between Substance Use and Symptoms of Sleep Disturbance {#S3-7}
--------------------------------------------------------------------

People who were at risk of hazardous/harmful/dependent drinking or who were current smokers were more likely to have pauses in breathing during sleep and disrupted sleep, while those who used cannabis or tranquilizers monthly or more frequently were more likely to have disrupted sleep. Monthly or more frequent amphetamine use was associated with lower incidence of pauses. Caffeine intake of \<200 mg/day was associated with a lower incidence of snoring and pauses in breathing during sleep (Table [8](#T8){ref-type="table"}).

###### 

**Univariate associations between substance use and symptoms of sleep disturbance**.

                                       Snore   Pause   Disruptive sleep                                                                                                                                                                                
  ------------------------------------ ------- ------- ---------------------------------------- ------------------- ----- ------ ------------------------------------------- ------------------- ----- ------ ---------------------------------------- -------------------
  **Alcohol risk (AUDIT)**                                                                                                                                                                                                                             
  Low                                  496     41.7    0.1                                      1.03 (0.84, 1.26)   185   15.9   5.5[\*](#tfn16){ref-type="table-fn"}        1.36 (1.05, 1.76)   627   51.1   9.7[\*\*](#tfn17){ref-type="table-fn"}   1.37 (1.12, 1.68)
  High                                 239     42.5    114                                      20.5                342   59                                                                                                                           
  **Current smoker**                                                                                                                                                                                                                                   
  No                                   242     42.2    0.0                                      0.99 (0.81, 1.21)   75    13.2   10.8[\*\*\*](#tfn18){ref-type="table-fn"}   1.6 (1.21, 2.13)    297   49.6   5.6[\*](#tfn16){ref-type="table-fn"}     1.27 (1.04, 1.54)
  Yes                                  490     42.0    223                                      19.6                663   55.5                                                                                                                         
  **Cannabis use -- past year**                                                                                                                                                                                                                        
  \<monthly                            304     40.6    0.0                                      1.02 (0.8, 1.3)     136   18.7   0.0                                         1.0 (0.75, 1.38)    391   51.0   9.8[\*\*](#tfn17){ref-type="table-fn"}   1.46 (1.15, 1.86)
  ≥monthly                             176     41.1    79                                       18.9                264   60.4                                                                                                                         
  **Amphetamine use -- past year**                                                                                                                                                                                                                     
  \<monthly                            256     41.6    0.6                                      0.84 (0.54, 1.31)   130   21.7   6.3[\*](#tfn16){ref-type="table-fn"}        0.43 (0.22, 0.84)   347   54.8   2.5                                      1.42 (0.92, 2.2)
  ≥monthly                             36      37.5    10                                       10.5                62    63.3                                                                                                                         
  **Tranquilizers use -- past year**                                                                                                                                                                                                                   
  \<monthly                            77      45.6    2.2                                      0.6 (0.3, 1.19)     43    26.1   0.0                                         0.95 (0.44, 2.03)   108   62.1   5.8[\*](#tfn16){ref-type="table-fn"}     2.58 (1.17, 5.68)
  ≥monthly                             15      33.3    11                                       25.0                38    80.9                                                                                                                         
  **Caffeine (mg/day)**                                                                                                                                                                                                                                
  \<200 mg                             252     37.3    9.8[\*\*](#tfn17){ref-type="table-fn"}   1.37 (1.15, 1.67)   95    14.3   7.4[\*\*](#tfn17){ref-type="table-fn"}      1.44 (1.11, 1.88)   372   53.6   0.0                                      1.0 (0.83, 1.21)
  ≥200 mg                              483     44.8    204                                      19.4                597   53.7                                                                                                                         

*OR, odds ratio; CI, confidence interval; AUDIT, Alcohol Use Disorders Identification Test*.

*\*p \< 0.05*.

*\*\*p \< 0.01*.

*\*\*\*p \< 0.001*.

Multiple Logistic Regression Models Adjusting for Multiple Confounders {#S3-8}
----------------------------------------------------------------------

After adjusting for gender, age, and BMI in multiple logistic regression models, the odds of pauses in breathing during sleep in participants with a positive history of cardiovascular disease remained 1.96 times (95% CI, 1.19, 3.48) higher than those without the history of cardiovascular disease. Participants who were at high risk of hazardous/harmful/dependent drinking had odds ratio of snoring 1.59 times (CI 1.07, 2.38) and pause in breathing during sleep 1.882 times (CI 1.15, 3.09) in low risk participants (Table [9](#T9){ref-type="table"}).

###### 

**Logistic regression model for the relationship between subjects' OSA symptoms and disease factors**.

                                                         Snore               Pause                                                                                           
  ------------------------------------------------------ ------------------- --------- ------------------- -------------- ------------------- --------- -------------------- -------------
  **Physical health**                                                                                                                                                        
  Metabolic syndrome IDF criteria                        1.84 (1.46, 2.32)   \<0.001   0.67 (0.41, 1.05)   NS             2.26 (1.66, 3.08)   \<0.001   0.632 (0.37, 1.09)   NS
  Absolute cardiovascular disease 5-year risk equation   1.56 (1.23, 1.98)   \<0.001   1.16 (0.67, 2.01)   NS             1.65 (1.23, 2.22)   \<0.001   1.325 (0.69, 2.54)   NS
  Any history of cardiovascular disease                  2.03 (1.64, 2.52)   \<0.001   1.40 (0.85, 2.30)   NS             2.19 (1.69, 2.84)   \<0.001   1.959 (1.19, 3.48)   *P* \< 0.05
  **Physical activities**                                                                                                                                                    
  Vigorous activity (h/week)                             1.27 (1.0, 1.6)     NS        1.22 (0.72, 2.06)   NS             1.6 (1.14, 2.26)    \<0.01    0.935 (0.48, 1.83)   NS
  Walk (h/week)                                          1.15 (0.95, 1.39)   NS        1.01 (0.58, 1.75)   NS             1.3 (1.0, 1.68)     \<0.5     0.771 (0.39, 1.52)   NS
  Total activity (h/week)                                1.3 (0.98, 1.73)    NS        0.81 (0.43, 1.50)   NS             1.53 (1.09, 2.16)   \<0.5     0.834 (0.39, 1.77)   NS
  **Social function**                                                                                                                                                        
  Formal activity (paid or unpaid work, or study)        0.97 (0.8, 1.17)    NS        1.38 (0.77, 2.50)   NS             0.72 (0.56, 0.93)   \<0.05    1.161 (0.59, 2.30)   NS
  Paid employment -- past year                           0.88 (0.72, 108)    NS        0.97 (0.47, 2.00)   NS             0.62 (0.47, 0.83)   \<0.01    0.927 (0.39, 2.19)   NS
  Paid employment -- past week                           0.95 (0.75, 1.2)    NS        0.86 (0.43, 1.71)   NS             0.55 (0.39, 0.77)   \<0.001   0.399 (0.16, 1.01)   NS
  **Substance abuse**                                                                                                                                                        
  Alcohol risk (AUDIT)                                   1.03 (0.84, 1.26)   NS        1.59 (1.07, 2.38)   *P* \< 0.05    1.36 (1.05, 1.76)   \<0.05    1.882 (1.15, 3.09)   *P* \< 0.05
  Current smoker                                         0.99 (0.81, 1.21)   NS        0.77 (0.43, 1.37)   NS             1.6 (1.21, 2.13)    \<0.001   0.746 (0.37, 1.51)   NS
  Amphetamine use -- past year                           0.84 (0.54, 1.31)   NS        1.53 (0.81, 2.89)   NS             0.43 (0.22, 0.84)   \<0.05    0.562 (0.22, 1.42)   NS
  Caffeine (mg/day)                                      1.37 (1.15, 1.67)   \<0.01    1.60 (1.03, 2.51)   *P* \< 0.01    1.44 (1.11, 1.88)   \<0.001   1.643 (0.94, 2.89)   NS
  **Gender**                                             1.43 (1.18, 1.73)   \<0.001   1.17 (0.76, 1.80)   NS             1.01 (0.78, 1.30)   NS        1.507 (0.89, 2.54)   NS
  **Age**                                                1.77 (1.46, 2.16)   \<0.001   2.21 (1.45, 3.39)   *P* \< 0.001   1.37 (1.06, 1.77)   \<0.05    1.141 (0.68, 1.91)   *P* \< 0.05
  **BMI**                                                2.16 (1.7, 2.7)     \<0.001   1.21 (0.73, 2.00)   NS             3.17 (2.16, 4.66)   \<0.001   2.236 (1.09, 4.58)   *P* \< 0.05

*OSA, obstructive sleep apnea; OR, odds ratio; CI, confidence interval; BMI, body mass index*.

Discussion {#S4}
==========

In this representative sample of people with psychotic illness, symptoms of OSA were highly prevalent, with rates of pauses in breathing during sleep and snoring 17.4 and 41.9%, respectively. However, these results are likely to be underestimates given that 83% of patients were neither married or in a *de facto* relationship and, thus, likely had no regular bed partner to notice these symptoms during sleep. Our results confirm and add precision to findings from previous studies with small samples of selected patients with schizophrenia ([@B15]--[@B18]). Further, the prevalence of OSA in our study sample was much higher than the prevalence of OSA in general population, which is estimated to be 3--5% ([@B1], [@B32]--[@B36]).

Our study has demonstrated that symptoms of OSA (snoring and pauses in breathing during sleep) were associated with higher likelihood of meeting at-risk criteria for key cardiometabolic risk factors. Symptoms of OSA were associated with a higher rate of a reported history of cardiovascular diseases. The association between pause in breathing during sleep and reported history of cardiovascular disease remained significant after adjusting for BMI, age, and gender. Previous studies in the general population have found that OSA is a significant independent risk factor for CVD-related mortality and a composite endpoint of all-cause mortality and incident stroke ([@B37]). Additionally, obesity, male gender, older age, and increased neck circumference are the most significant risk factors for OSA. Thus, it is likely that OSA and obesity may impact on each other to set up a vicious cycle, thereby creating severe cardiometabolic disease.

We found that OSA symptoms, such as snoring and pauses in breathing during sleep, did not impact on the severity of psychopathology, including depressive, psychotic, and manic symptoms, except anxiety symptoms. Disrupted sleep was associated with more severe symptoms in all domains measured. We are not aware of any previous studies examining the associations between OSA and psychopathology in people with psychosis; however, a number of case studies have reported a reduction in positive and negative symptoms of psychosis when Continuous Positive Airway Pressure (CPAP) treatment was initiated ([@B38]--[@B41]).

Our results revealed an unexpected finding. People prescribed with more obesogenic and sedative atypical antipsychotics were less likely to report subjective sleep disturbances, than those who were prescribed other psychotropic drugs. This contradicts an earlier retrospective study, which found that atypical antipsychotic medications were independently associated with OSA, and that individuals taking atypical antipsychotics had more severe sleep apnea when adjusted for BMI, sex, and use of benzodiazepines and sleeping aids ([@B42]). It has been suggested that the sedative actions of atypical antipsychotics may reduce activity of the hypoglossal and recurrent laryngeal nerve on upper airway musculature; however, this is not reflected in our data. The finding that the use of atypical antipsychotics is associated with reduced odds of disrupted sleep could be explained by the hypnotic effects of these medications, which could possibly cause a reduction in reported sleep symptoms. Another explanation for the difference between our results and Rishi et al. ([@B42]) is that Rishi compared people taking atypical antipsychotics with participants who were not taking any hypnotic medication, whereas we have compared people with psychotic illnesses on a variety of typical antipsychotics, atypical antipsychotics, mood stabilizers, and benzodiazepines. Interestingly, our study showed that the use of mood stabilizers and antidepressants was associated with symptoms of OSA. As mood stabilizers and antidepressants are commonly used as adjunctive medications in psychosis, this finding suggests that the prescribing of these drugs may increase the risk of OSA. Another possible explanation for this new finding is, people with OSA may be more depressed and fatigued and, therefore, more likely to be prescribed antidepressants and mood stabilizers.

Pauses in breathing during sleep, indicating the more severe form of OSA, were associated with lower rates of employment or study. Evaluation of health-related quality of life showed that our participants reporting more severe form of symptoms of OSA had significant impairments in the domains of independent living and psychological well-being. It is possible that current sleep symptoms may negatively impact on social participation; alternatively, people who are disengaged from social activity may also sleep poorly, perhaps as a result of depression or poor physical health. However, if sleep disorders do cause a reduction in social function, treatment of these disorders could be associated with improved function and productivity. This hypothesis could be tested in clinical trials.

In this study, we found that symptoms of sleep apnea and symptoms of disrupted sleep impact on different clinical domains in people with psychosis. Symptoms of sleep apnea are more likely to have negative relationship with people's cardiometabolic risk, social participation, and physical activity, while disrupted sleep has stronger association with active psychiatric symptoms. This suggests that the mechanism of the effect of sleep apnea on patients' clinical outcomes is different from sleep deprivation alone.

In conclusion, this study provides robust evidence that sleep disorders are prevalent in people with psychotic illness and may contribute a further risk factor for cardiovascular disease. The disease-specific determinants of OSA in people with psychosis should be elucidated in future studies. Further investigation and treatment of OSA in people with psychosis may be beneficial in reducing the burden of cardiovascular disease, productivity, and quality of life.

Limitations {#S4-1}
-----------

This study had several limitations: The inherent biases of observational data without clear objectives apply to this study. The measures of symptoms of sleep apnea are indirect and self-reported. This study did not specifically examine the polypharmacy interaction or the medication compliance. Due to the nature of cross-sectional study, we can only identify associations in the data.
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